Rodriguez-Tudela Juan L, Diaz-Guerra Teresa M, Mellado Emilia, Cano Virginia, Tapia Cecilia, Perkins Alexander, Gomez-Lopez Alicia, Rodero Laura, Cuenca-Estrella Manuel
Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Antimicrob Agents Chemother. 2005 Oct;49(10):4026-34. doi: 10.1128/AAC.49.10.4026-4034.2005.
The physiological patterns, the sequence polymorphisms of the internal transcriber spacer (ITS), and intergenic spacer regions (IGS) of the rRNA genes and the antifungal susceptibility profile were evaluated for their ability to identify Trichosporon spp. and their specificity for the identification of 49 clinical isolates of Trichosporon spp. Morphological and biochemical methodologies were unable to differentiate among the Trichosporon species. ITS sequencing was also unable to differentiate several species. However, IGS1 sequencing unambiguously identified all Trichosporon isolates. Following the results of DNA-based identification, Trichosporon asahii was the species most frequently isolated from deep sites (15 of 25 strains; 60%). In the main, other Trichosporon species were recovered from cutaneous samples. The majority of T. asahii, T. faecale, and T. coremiiforme clinical isolates exhibited resistance in vitro to amphotericin B, with geometric mean (GM) MICs >4 mug/ml. The other species of Trichosporon did not show high MICs of amphotericin B, and GM MICs were <1 mug/ml. Azole agents were active in vitro against the majority of clinical strains. The most potent compound in vitro was voriconazole, with a GM MIC </=0.14 mug/ml. The sequencing of IGS correctly identified Trichosporon isolates; however, this technique is not available in many clinical laboratories, and strains should be dispatched to reference centers where these complex methods are available. Therefore, it seems to be more practical to perform antifungal susceptibility testing of all isolates belonging to Trichosporon spp., since correct identification could take several weeks, delaying the indication of an antifungal agent which exhibits activity against the infectious strain.
对生理模式、核糖体RNA基因的内转录间隔区(ITS)和基因间间隔区(IGS)的序列多态性以及抗真菌药敏谱进行了评估,以确定其在鉴定毛孢子菌属菌种方面的能力及其对49株临床分离毛孢子菌属菌种鉴定的特异性。形态学和生化方法无法区分毛孢子菌属的不同菌种。ITS测序也无法区分几个菌种。然而,IGS1测序明确鉴定了所有毛孢子菌属分离株。根据基于DNA的鉴定结果,阿萨希毛孢子菌是从深部部位最常分离出的菌种(25株中的15株;60%)。主要地,其他毛孢子菌属菌种是从皮肤样本中分离得到的。大多数阿萨希毛孢子菌、粪便毛孢子菌和帚状毛孢子菌临床分离株在体外对两性霉素B耐药,几何平均(GM)最低抑菌浓度(MIC)>4μg/ml。其他毛孢子菌属菌种未显示出两性霉素B的高MIC值,GM MIC<1μg/ml。唑类药物在体外对大多数临床菌株有活性。体外最有效的化合物是伏立康唑,GM MIC≤0.14μg/ml。IGS测序正确鉴定了毛孢子菌属分离株;然而,这项技术在许多临床实验室无法获得,菌株应送至具备这些复杂方法的参考中心。因此,对所有毛孢子菌属菌种的分离株进行抗真菌药敏试验似乎更实际,因为正确鉴定可能需要数周时间,从而延迟了对具有针对感染菌株活性的抗真菌药物的使用指示。